Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes

Courage, C; Oliver, KL; Park, EJ; Cameron, JM; Grabińska, KA; Muona, M; Canafoglia, L; Gambardella, A; Said, E; Afawi, Z; Baykan, B; Brandt, C; Di Bonaventura, C; Chew, HB; Criscuolo, C; Dibbens, LM; Castellotti, B; Riguzzi, P; Labate, A; Filla, A; Giallonardo, AT; Berecki, G; Jackson, CB; Joensuu, T; Damiano, JA; Kivity, S; Korczyn, A; Palotie, A; Striano, P; Uccellini, D; Giuliano, L; Andermann, E; Scheffer, IE; Michelucci, R; Bahlo, M; Franceschetti, S; Sessa, WC; Berkovic, SF; Lehesjoki, AE

Author(s): Courage, C; Oliver, KL; Park, EJ; Cameron, JM; Grabińska, KA; Muona, M; Canafoglia, L; Gambardella, A; Said, E; Afawi, Z; Baykan, B; Brandt, C; Di Bonaventura, C; Chew, HB; Criscuolo, C; Dibbens, LM; Castellotti, B; Riguzzi, P; Labate, A; Filla, A; Giallonardo, AT; Berecki, G; Jackson, CB; Joensuu, T; Damiano, JA; Kivity, S; Korczyn, A; Palotie, A; Striano, P; Uccellini, D; Giuliano, L; Andermann, E; Scheffer, IE; Michelucci, R; Bahlo, M; Franceschetti, S; Sessa, WC; Berkovic, SF; Lehesjoki, AE;
Details: Publication Year 2021-04-01,Volume 108,Issue #4,Page 722-738
Journal Title: American Journal of Human Genetics
Abstract: Progressive myoclonus epilepsies (PMEs) comprise a group of clinically and genetically heterogeneous rare diseases. Over 70% of PME cases can now be molecularly solved. Known PME genes encode a variety of proteins, many involved in lysosomal and endosomal function. We performed whole-exome sequencing (WES) in 84 (78 unrelated) unsolved PME-affected individuals, with or without additional family members, to discover novel causes. We identified likely disease-causing variants in 24 out of 78 (31%) unrelated individuals, despite previous genetic analyses. The diagnostic yield was significantly higher for individuals studied as trios or families (14/28) versus singletons (10/50) (OR = 3.9, p value = 0.01, Fisher's exact test). The 24 likely solved cases of PME involved 18 genes. First, we found and functionally validated five heterozygous variants in NUS1 and DHDDS and a homozygous variant in ALG10, with no previous disease associations. All three genes are involved in dolichol-dependent protein glycosylation, a pathway not previously implicated in PME. Second, we independently validate SEMA6B as a dominant PME gene in two unrelated individuals. Third, in five families, we identified variants in established PME genes; three with intronic or copy-number changes (CLN6, GBA, NEU1) and two very rare causes (ASAH1, CERS1). Fourth, we found a group of genes usually associated with developmental and epileptic encephalopathies, but here, remarkably, presenting as PME, with or without prior developmental delay. Our systematic analysis of these cases suggests that the small residuum of unsolved cases will most likely be a collection of very rare, genetically heterogeneous etiologies.
Publisher: Elsevier
Keywords: dolichol-dependent glycosylation; epilepsy genetics; progressive myoclonus epilepsy; whole-exome sequencing
Research Division(s): Population Health And Immunity
PubMed ID: 33798445
Publisher's Version: https://doi.org/10.1016/j.ajhg.2021.03.013
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2021-05-11 01:34:13

Last Modified: 2021-05-11 01:51:31